VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

TCT 2021 | Flotetuzumab as salvage therapy for primary induction failure and early AML

Ibrahim Aldoss, MD, City of Hope National Medical Center, Duarte, CA, discusses updated results of the first-in-human study of flotetuzumab, an investigational CD123 x CD3 bi-specific product currently in development for patients with acute myeloid leukemia (AML). Flotetuzumab has demonstrated encouraging activity in patients with primary induction failure and early relapse AML, which represents a population with poor prognosis and unmet need. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter